We are pleased to announce that PredictCan Biotechnologies joined the North American 3Rs collaborative as a bronze-level initiative member. The 3Rs collaborative is a non-profit organization that facilitates collaborative opportunities between academics, pharmaceutical companies, contract research organizations, government organizations, and regulatory agents to refine, reduce, and replace animals in research.

We are pleased to announce that our original research article on the capability of individual-centric spheroid model to detect immune-mediated idiosyncratic DILI at therapeutic doses has just been published in Frontiers in Pharmacology, section Predictive Toxicology. « Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver

Predictcan Biotechnologies has obtained the financial support of the “Région Occitanie” and of the government as part of the “Plan France 2030” to accelerate the development of a companion diagnostic test for hepatocellular carcinoma. Predictcan Biotechnologies collaborates with clinicians to develop innovative solutions for an optimal care for each patient.

French Tech Seed Label Predictcan Biotechnologies is proud to announce that the company has been awarded the label “French Tech Seed” by the Occitanie Tech Seed Consortium with the Satt AxLR as leader. The investment funds French Tech Seed from the Future Investment Program is operated by BPI France. It

PredictCan Biotechnologies moved to a new location and acquired new lab equipment. You can find us now at: Biopôle Euromédecine 1682 Rue de la Valsière, 34790 Grabels Cap Sigma 3rd floor

We are happy to share our latest article published in “In vitro models” describing an individual-centric 3D model to predict drug-induced liver injury based on non-genetic host factors. GenuineSelect-TOX is a powerful and highly sensitive human 3D model that can detect interindividual differences of drug-induced liver injury at preclinical stage.